Skip to main content Accessibility help
×
Home

The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre

  • A. L. Hart (a1) and P. Hendy (a1)

Abstract

Inflammatory bowel disease (IBD) is increasing in incidence in both the developed and the developing world. Genetic, immunological and environmental factors are known to be involved. Genome-wide studies have examined the contribution played by host genetics in the development of IBD and have estimated that genetic factors are responsible for about 25 % of the disease risk. Having an IBD-associated genotype does not always lead to development of the disease phenotype, and hence it seems likely that environmental factors are key to triggering development of the disease in genetically susceptible individuals. The gut microbiota contains more cells than its human host, and mounting evidence attests to the importance of the microbiota in the development of several diseases, including IBD, metabolic syndrome and CVD. The present paper reviews the interplay between the microbiota and the mucosal immune system in health and in IBD; and discusses the evidence base for the use of therapeutic modulation of the microbiota to prevent and treat IBD.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: A. L. Hart, email Ailsa.Hart@nhs.net

References

Hide All
1. Duerkop, BA, Vaishnava, S & Hooper, LV (2009) Immune responses to the microbiota at the intestinal mucosal surface. Immunity 31(3), 368376.
2. Sekirov, I, Russell, SL, Antunes, LCM et al. (2010) Gut microbiota in health and disease. Physiol Rev 90, 859904.
3. Peterson, DA, Frank, DN, Pace, NR et al. (2008) Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe 3, 417427.
4. Fraher, MH, O'Toole, PW & Quigley, EMM (2012) Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 9, 312322.
5. Swidsinski, A, Loening-Baucke, V, Lochs, H et al. (2005) Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol 11, 1131–140.
6. Hooper, LV, Wong, MH, Thelin, A et al. (2001) Molecular analysis of commensal host–microbial relationships in the intestine. Science 291(5505), 881884.
7. Garrett, WS, Lord, GM, Punit, S et al. (2007) Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 3345.
8. Biswas, A & Kobayashi, KS (2013) Regulation of intestinal microbiota by the NLR protein family. Int Immunol 25, 207214.
9. Secher, T, Normand, S & Chamaillard, M (2014) NOD2 prevents emergence of disease-predisposing microbiota. Gut Microbes 4, 353–336.
10. Vrieze, A, Holleman, F, Zoetendal, EG et al. (2010) The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53, 606613.
11. Xavier, RJ & Podolsky, DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427434.
12. Barrett, JC, Lee, JC, Lees, CW et al. (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41, 13301334.
13. Anderson, CA, Boucher, G, Lees, CW et al. (2011) Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 43, 246252.
14. Sartor, RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577594.
15. D'Haens, GR, Geboes, K, Peeters, M et al. (1998) Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114, 262267.
16. Sartor, RB, Blumberg, RS, Braun, J et al. (2007) CCFA microbial–host interactions workshop: highlights and key observations. Inflamm Bowel Dis 13, 600619.
17. Selby, W, Pavli, P, Crotty, B et al. (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132, 23132319.
18. Darfeuille-Michaud, A, Boudeau, J, Bulois, P et al. (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127, 412421.
19. Sokol, H, Seksik, P, Furet, JP et al. (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15, 11831189.
20. Erickson, AR, Cantarel, BL, Lamendella, R et al. (2012) Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohn's disease. PLoS ONE 7, e49138.
21. Dominguez-Bello, MG, Costello, EK, Contreras, M et al. (2010) Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 107, 1197111975.
22. Bager, P, Simonsen, J, Nielsen, NM et al. (2012) Cesarean section and offspring's risk of inflammatory bowel disease: a national cohort study. Inflamm Bowel Dis 18, 857862.
23. Cabrera-Rubio, R, Collado, MC, Laitinen, K et al. (2012) The human milk microbiome changes over lactation and is shaped by maternal weight and mode of delivery. Am J Clin Nutr 96, 544551.
24. Khalili, H, Ananthakrishnan, AN, Higuchi, LM et al. (2013) Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm Bowel Dis 19, 542547.
25. Spooren, CEGM, Pierik, MJ, Zeegers, MP et al. (2013) Review article: the association of diet with onset and relapse in patients with inflammatory bowel disease. Aliment Pharmacol Ther 38, 11721187.
26. Navas López, VM, Blasco Alonso, J, Sierra Salinas, C et al. (2008) Efficacy of exclusive enteral feeding as primary therapy for paediatric Crohn's disease. An Pediatr (Barc) 69, 506514.
27. Akobeng, AK & Thomas, AG (2007) Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev, CD005984.
28. Thibault, R, Blachier, F, Darcy-Vrillon, B et al. (2010) Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16, 684695.
29. Wong, JMW, de Souza, R, Kendall, CWC et al. (2006) Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 40, 235243.
30. Marchesi, JR, Holmes, E, Khan, F et al. (2007) Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 6, 546551.
31. Vieira, ELM, Leonel, AJ, Sad, AP et al. (2012) Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. J Nutr Biochem 23, 430436.
32. Farrukh, A & Mayberry, JF (2014) Is there a role for fish oil in inflammatory bowel disease? World J Clin Cases 2, 250252.
33. Yates, CM, Calder, PC & Ed Rainger, G (2014) Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease. Pharmacol Ther 141, 272282.
34. Mouli, VP & Ananthakrishnan, AN (2014) Review article: vitamin D and inflammatory bowel diseases. Aliment Pharmacol Ther 39, 125136.
35. D'Haens, GR, Vermeire, S, Van Assche, G et al. (2008) Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135, 11231129.
36. Prantera, C, Lochs, H, Grimaldi, M et al. (2012) Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 142, 473481. e4.
37. Holubar, SD, Cima, RR, Sandborn, WJ et al. (2010) Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev, CD001176.
38. Gionchetti, P, Rizzello, F, Helwig, U et al. (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124, 12021209.
39. Mimura, T, Rizzello, F, Helwig, U et al. (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108114.
40. Kruis, W, Schütz, E, Fric, P et al. (1997) Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11, 853858.
41. Sood, A, Midha, V, Makharia, GK et al. (2009) The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7, 12021209.e1.
42. Bourreille, A, Cadiot, G, Le Dreau, G et al. (2013) Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 11, 982987.
43. Shen, J, Ran, HZ, Yin, MH et al. (2009) Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. Intern Med J 39, 103109.
44. Rahimi, R, Nikfar, S, Rahimi, F et al. (2008) A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 53, 25242531. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18270836.
45. Van Gossum, A, Dewit, O, Louis, E et al. (2007) Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 13, 135142.
46. Lindsay, JO, Whelan, K, Stagg, AJ et al. (2006) Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348355.
47. Benjamin, JL, Hedin, CRH, Koutsoumpas, A et al. (2011) Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 60, 923929.
48. Joossens, M, De Preter, V, Ballet, V et al. (2012) Effect of oligofructose-enriched inulin (OF-IN) on bacterial composition and disease activity of patients with Crohn's disease: results from a double-blinded randomised controlled trial. Gut 61, 958.
49. Rager, KD, George, LW, House, JK et al. (2004) Evaluation of rumen transfaunation after surgical correction of left-sided displacement of the abomasum in cows. J Am Vet Med Assoc 225, 915920.
50. Eiseman, B, Silen, W, Bascom, GS et al. (1958) Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44, 854859.
51. Van Nood, E, Vrieze, A, Nieuwdorp, M et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 368, 407415.
52. Borody, TJ & Khoruts, A (2012) Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol 9, 8896.
53. Vrieze, A, Van Nood, E, Holleman, F et al. (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913916. e7.
54. Kassam, Z, Lee, CH, Yuan, Y & Hunt, RH (2013) Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 108, 500508.
55. Grehan, MJ, Borody, TJ, Leis, SM et al. (2010) Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 44, 551561.
56. Lawley, TD, Clare, S, Walker, AW et al. (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog 8, e1002995.
57. Shanahan, F (2009) Therapeutic implications of manipulating and mining the microbiota. J Physiol 587, Pt 17, 41754179.

Keywords

Related content

Powered by UNSILO

The microbiome in inflammatory bowel disease and its modulation as a therapeutic manoeuvre

  • A. L. Hart (a1) and P. Hendy (a1)

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.